Phil Gross, PhD
banner
philgrossphd.bsky.social
Phil Gross, PhD
@philgrossphd.bsky.social
Postdoctoral Fellow at NIH Center for Alzheimer’s and Related Dementias. #TDP43 #Organoids #Neuroimmunology Prior: @GeorgetownBGE. Views are my own
Reposted by Phil Gross, PhD
We built in the US the best scientific industry in world history and it is dying.

Fixing just the damage done since Jan 20 would take years. Maybe a decade. The program staff, SROs, and brilliant talent is not coming back.
March 20, 2025 at 2:46 AM
Thanks! Complimentary results to what you found in EAE
March 7, 2025 at 6:53 PM
Thanks! So far I think information is limited on D/Q ability to cross the BBB, but this study here (doi.org/10.1038/s415...) shows elevated levels in csf of D but not Q. Newer next generation senolytics that target apoptosis pathways better may cross better though.
Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial - Nature Medicine
The first feasibility study of orally delivered senolytic therapy in Alzheimer’s disease reports favorable safety data and penetrance of dasatinib into the brain with a modest impact on Alzheimer’s an...
doi.org
March 7, 2025 at 5:19 PM
A big thank you to my mentor @jkhuang.bsky.social and members of the lab @zeebamehrin.bsky.social and all of our collaborators who were amazing to work with @mengmengfu.bsky.social @jrplemel.bsky.social

3/3
March 7, 2025 at 1:59 PM
We find this is (partially) mediated by CCL11, which we find is sufficient to limit oligodendrocyte maturation, and has been shown to impair neuro-regeneration w/ age and is involved in long covid neurological deficits (as shown by @michellemonje.bsky.social, among others)

2/3
March 7, 2025 at 1:58 PM